Background: Acute pancreatic inflammation is an emergency worldwide. Aprimelast
(Otezla) is an orally active drug inhibiting phosphodiesterase-4 (PDE4) &modulate the
inflammatory mediators. NO research was done to detect its role in treatment of acute
pancreatitis (AP). Aim: this research was designed to determine the role of Aprimelast on AP
produced by L-arginine. Materials & methods: A rat model of AP was developed by two
injections of L-arginine 250 mg/kg body weight, intraperitoneal (IP), separated by a one-hour
period. The treatment group received Aprimelast at a single daily oral dosage of 20mg/kg
body weight for five consecutive days after IP injections of L-arginine at the same dose as
before.AT the last of treating period, blood samples were taken for the assessment of the
parameters of oxidative stress glutathione [GSH], malondialdehyde [MDA], then rats were
sacrificed. The pancreas of all treated animals was excised, prepared for estimation of tumor
necrotic factor (TNF- alpha) & interleukin-10 (IL-10) in tissues and histopathological
examination. Results: Rats with AP had histological alterations consistent with pancreatic
tissue impairment, and elevated blood glucose, serum amylase, and lipase enzyme activities.
Additionally, AP rats had increased levels of the pancreatic inflammatory biomarker TNFalpha and decreased levels of the anti-inflammatory biomarker IL-10. Additionally, the
oxidative stress biomarker MDA was elevated in AP, whereas the antioxidant GSH level was
reduced as contrasted to control group. Co-administration of Aprimelast led to substantial
improvements in both pre-existing parameters and histology. Conclusion: These results
suggested that Aprimelast may have beneficial therapeutic effect on L- arginine induced AP
in adult albino rats owing to its anti-inflammatory and anti-oxidative stress effects |
